share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股sec公告 ·  05/11 04:51
牛牛AI助理已提取核心訊息
TransCode Therapeutics, Inc., a biotech company, has announced its intention to appeal a delisting notice from the Nasdaq Stock Market. The company received the notice on May 7, 2024, indicating that it had failed to comply with the Nasdaq's Minimum Bid Price Rule by not maintaining a minimum closing bid price of $1.00 per share. TransCode Therapeutics was given until May 6, 2024, to regain compliance but was unable to meet the requirement. Additionally, the company did not meet the $5,000,000 minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The company plans to request a hearing before a Nasdaq Hearings Panel by May 14, 2024, to address the deficiencies and present a plan to regain compliance. Until the hearing process concludes, the company's common stock will remain listed and eligible for trading on Nasdaq. However, there is no guarantee that TransCode Therapeutics will be able to regain compliance and avoid delisting.
TransCode Therapeutics, Inc., a biotech company, has announced its intention to appeal a delisting notice from the Nasdaq Stock Market. The company received the notice on May 7, 2024, indicating that it had failed to comply with the Nasdaq's Minimum Bid Price Rule by not maintaining a minimum closing bid price of $1.00 per share. TransCode Therapeutics was given until May 6, 2024, to regain compliance but was unable to meet the requirement. Additionally, the company did not meet the $5,000,000 minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market. The company plans to request a hearing before a Nasdaq Hearings Panel by May 14, 2024, to address the deficiencies and present a plan to regain compliance. Until the hearing process concludes, the company's common stock will remain listed and eligible for trading on Nasdaq. However, there is no guarantee that TransCode Therapeutics will be able to regain compliance and avoid delisting.
生物技術公司TransCode Therapeutics, Inc. 宣佈打算對納斯達克股票市場的退市通知提出上訴。該公司於2024年5月7日收到通知，表明它沒有維持每股1.00美元的最低收盤價，從而未能遵守納斯達克的最低出價規則。TransCode Therapeutics在2024年5月6日之前獲准恢復合規，但未能滿足要求。此外，該公司未達到在納斯達克資本市場首次上市的500萬美元最低股東權益要求。該公司計劃在2024年5月14日之前要求納斯達克聽證會小組舉行聽證會，以解決缺陷並提出恢復合規的計劃。在聽證會結束之前，該公司的普通股將繼續上市並有資格在納斯達克交易。但是，無法保證TransCode Therapeutics能夠恢復合規並避免退市。
生物技術公司TransCode Therapeutics, Inc. 宣佈打算對納斯達克股票市場的退市通知提出上訴。該公司於2024年5月7日收到通知，表明它沒有維持每股1.00美元的最低收盤價，從而未能遵守納斯達克的最低出價規則。TransCode Therapeutics在2024年5月6日之前獲准恢復合規，但未能滿足要求。此外，該公司未達到在納斯達克資本市場首次上市的500萬美元最低股東權益要求。該公司計劃在2024年5月14日之前要求納斯達克聽證會小組舉行聽證會，以解決缺陷並提出恢復合規的計劃。在聽證會結束之前，該公司的普通股將繼續上市並有資格在納斯達克交易。但是，無法保證TransCode Therapeutics能夠恢復合規並避免退市。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。